Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?

S. Foghsgaard, L. Vedtofte, E. Bahne, C. Andreasen, L. K. Christiansen, J. A. Svare, T. D. Clausen, E. R. Mathiesen, P. Damm, L. L. Gluud, F. K. Knop, T. Vilsboll

Original languageEnglish
JournalDiabetologia
Volume60
Pages (from-to)S369-S369
ISSN0012-186X
Publication statusPublished - 2017

Cite this